Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α β DBM is a human allograft-derived demineralized bone matrix (DBM) developed by Alpha-Beta Technologies for use in bone-related surgical procedures. The product is processed to maintain the natural collagen scaffold and essential growth factors, particularly bone morphogenetic proteins (BMPs), which are critical for bone regeneration. By removing the mineral content, the bioavailability of these osteoinductive proteins is increased, allowing the graft to actively recruit and induce the differentiation of progenitor cells into bone-forming osteoblasts. Simultaneously, the matrix provides an osteoconductive environment that supports the attachment and proliferation of new bone cells. It is typically used in spinal fusions, orthopedic trauma repair, and dental reconstructions to fill bone voids and facilitate fusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on α β DBM.